Schering Corporation

Merck Sharp + Dohme Corp.

Other

Razia Rizvi

Joseph A Kozlowski

Bandarpalle B Shankar

Ling Tong

Brian J Lavey

Neng-Yang Shih

Wensheng Yu

Dansu Li

Michael K C Wong

Guowei Zhou

De-Yi Yang

Kristin E Rosner

M Arshad Siddiqui

Janeta Popovici-Muller

Ronald L Wolin

Bin Hu

Lei Chen

Vinay M Girijavallabhan

Seong Heon Kim

Chaoyang Dai

Luke Fire

James M Spitler

Aneta M Micula

Michael K Wong

Vincent Stewart Madison

Zhuyan Guo

Peter Orth

Stuart W McCombie

Eric J Gilbert

Wei Wei

Dahai Wang

Seong-Heon Kim

Deyou Sha

Tao Ji

Bin Zhong

Robert Feltz

Judson E Richard

Aneta Maria Kosinski

Liping Yang

Oleg B Selyutin

Jae-Hun Kim

Jinglai Hao

Shankar B Bandarpalle

Aneta Maria Kosinzki

Chunli Huang

Kristen E Rosner

Shuai Zan

Michael KC Wong

Aneta S Micula

Robert Schering-Plough Corporation Feltz

The present invention relates to novel Heterocycle-Substituted Tetracyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, A', RR, Rand R are as defined herein. The present invention also relates to compositions comprising at least one Heterocycle-Substituted Tetracyclic Compound, and methods of using the Heterocycle-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient. 

Heterocycle-substituted tetracyclic compounds and methods of use thereof for the treatment of viral diseases

This invention relates to compounds of the Formula (I) as described herein, or a pharmaceutically acceptable salt, solvate or ester thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof. 

Compounds for the treatment of inflammatory disorders

This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof. 

This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF&#x2014;or combinations thereof. 

This invention relates to compounds of the Formula (I)-(IX):, as defined herein, or a pharmaceutically acceptable salt, solvate or ester thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF-&#x3b1; combinations thereof. 

Compounds for the treatment of inflammatory diseases

This invention relates to compounds of the Formula (I): 

Compounds of Formula I: and/or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions containing such compounds exhibit anti-inflammatory and immunomodulatory activity, and can be effective in treating cancer and inflammatory, immunomodulatory or respiratory diseases or conditions.

Cannabinoid receptor ligands

There are disclosed compounds of the formula a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; which exhibit anti-inflammatory and immunodulatory activity. Also disclosed are pharmaceutical compositions containing said compounds and methods of using the compounds for the treatment of various diseases and conditions.

There are disclosed compounds of the formula I a pharmaceutically acceptable salt or solvate of the compound, which exhibit anti-inflammatory and immunomodulatory activity. Also disclosed are pharmaceutical compositions containing said compounds.

Growing community of inventors

Bloomfield, NJ, United States of America

Razia Rizvi